Introduction
Osteoarthritis (OA) is the most common joint disorder in the world.
According to the World Health Organisation, OA affects 190 million people worldwide, thereby representing a major cause for pain and disability, especially in the aging population.
The main pathologic features are loss of articular cartilage, accompanied by hypertrophy in the subchondral bone and the joint margin. The pathogenesis of OA is poorly understood, but a major feature is the loss of aggrecan from the cartilage matrix (1) . The key components of the cartilage ECM are type II collagen and aggrecan, which make up to 90% of the dry weight of healthy cartilage. Aggrecan hydrates the collagen network and thus provides cartilage with its properties of compressibility and elasticity. Maintenance of aggrecan content in articular cartilage is therefore critical to the function of the tissue. Aggrecan monomers consist of a 250-kDa-protein core with chondroitin sulfate and keratan sulfate glycosaminoglycan (GAG) side chains attached to it, resulting in a molecule of 1 to 2 million Da molecular mass. The amino terminal region of the aggrecan core protein contains two globular domains, G1 and G2, which are separated by an interglobular domain (IGD) that spans about 150 amino residues. The G2 region is followed by a long GAG attachment region and by the C-terminal globular domain G3 (2, 3) . Aggrecan monomers interact with hyaluronan through their G1 domain and thus form large aggregates containing 10-100 aggrecan monomers on a hyaluronan backbone. (4) (5) (6) (7) . A second class of enzymes, for a long time known as an activity given the name "aggrecanase", cleaves the aggrecan core protein at another site in the IGD, between Glu 373 and Ala 374 (8) (9) (10) (11) .
Interestingly, aggrecan fragments in inflammatory and OA synovial fluid appear to be generated by cleavage at this second site between Glu 373 and Ala 374 (12, 13) . Two cartilage aggrecanases, aggrecanase 1 or ADAM-TS4 (14) and aggrecanase 2 or ADAM-TS5 (15) have recently been identified and cloned. Both enzymes belong to the a disintegrin and metalloprotease with thrombospondin motifs (ADAM-TS)
family of zinc metalloproteases that consist of an N-terminal propeptide domain, a metalloproteinase domain, a disintegrin-like domain, and a varying number of thrombospondin type 1 motifs, the sequence of which is the conserved motif in thrombospondin 1 and 2 (16) .
Both ADAM-TS4 and ADAM-TS5 cleave aggrecan within the IGD at the aggrecanase site between residues Glu 373 -Ala 374 at concentrations as low as 50 pM of enzyme, but at these concentrations do not cleave at the MMP site between residues (Fig.1) . These sites correspond with fragments previously reported to be released during IL-1α-treatment of bovine articular cartilage (9,18). Neoepitope Ab to the aggrecan fragments generated by cleavage at the ADAM-TS4/ADAM-TS5-preferred sites provide a specific tool for confirming the involvement of these enzymes in aggrecan breakdown. Consistent with other models of aggrecan catabolism (23, 24) , it was thus established that aggrecan fragments released during IL-1 treatment of bovine articular cartilage are the result of cleavage at all the ADAM-TS4/ADAM-TS5 sites, suggesting that these are the enzymes involved in aggrecan degradation in this model (25) .
Despite several reports in the literature implicating aggrecanase-activity in human OA (12, 13, 26, 27) , no evidence has been reported to demonstrate that ADAM-TS4/ADAM-TS5 are responsible for aggrecan breakdown in OA and more importantly, whether or not the breakdown in OA cartilage can be blocked. The current study was undertaken to address these issues. ADAM-TS1, ADAM-TS4, and ADAM-TS5 were cloned and expressed in Drosophila of these compounds against MMP-1, -2, -3, -8, -9 and -14 were calculated using the fluorogenic peptide substrate, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 , at a concentration of 1 µM, and against ADAM-TS4 and ADAM-TS5 were determined using 500 nM purified bovine nasal aggrecan as described (22 Pharmaceuticals and found to be highly reactive and specific for the respective neoepitopes, as previously described (22).
ADAM-TS Ab -Polyclonal Ab for ADAM-TS4 and ADAM-TS5 were prepared to the peptide sequences ILTSIDASKP (residues 502-511), VMAHVDPEEP (residues 502-511) and DAKQCASLNG (residues 481-490), respectively, as previously described (25) .
RT-PCR for ADAM-TS4 and ADAM-TS5 -RT-PCR for ADAM-TS4 and ADAM-
TS5 was performed as previously described (25) . Glycosaminoglycan assay -Sulfated GAG levels in the culture media were determined by the dimethylmethylene blue (DMMB) assay, as previously described (30) .
Deglycosylation of aggrecan and aggrecan catabolites -Proteoglycans and their
breakdown products were digested with keratanase (0.001 units per µg GAG), keratanase II (0.01 units per µg GAG), and chondroitinase ABC (0.001 units per µg GAG) and prepared for gel electrophoresis, as previously described (25) .
Western blot analysis -Twenty µl of the pooled media for each treatment were analyzed by SDS-PAGE on 4-12% polyacrylamide gels under reducing conditions.
The separated proteins were then transferred to PVDF membranes and immunolocalized with a 1:1000 dilution of one of the neoepitope Ab, as described (25) . 
Results

MMPs do not cleave aggrecan at the aggrecanase-preferred sites
In order to determine whether neoepitope Ab that detect cleavage at the aggrecanase-sensitive sites within the C-terminal region of the aggrecan core protein may serve as specific tools for monitoring ADAM-TS4/ADAM-TS5-activity in cartilage, we assessed the ability of these sites to be cleaved by other proteases. We OA cartilage explants release aggrecan fragments that contain aggrecanasegenerated, but not MMP-generated neoepitopes.
Aggrecan extracted from cartilage was analyzed by Western blot for MMPgenerated IPEN 341 and aggrecanase-generated TEGE 373 -containing products. Both the IPEN 341 and the TEGE 373 epitopes were detected in normal and OA cartilage, with no apparent change in OA cartilage (Fig.3a) . The presence of a 64-kDa fragment with the IPEN 341 C-terminus and a 70-kDa fragment with the C-terminus TEGE 373 in nonarthritic cartilage was a reproducible finding in cartilage from several individuals, as has been reported previously (26,27,33). We could detect these neoepitopes in cartilage from a donor as young as 7 weeks old (data not shown). This suggests that these fragments are retained in the matrix through the interaction of the G1 domain with hyaluronan and thus accumulate in cartilage during development and during the analysis and observing any change in disease will therefore be very difficult, and hence they will not be useful in providing an accurate parameter of aggrecanase-or MMP-activity in OA.
Therefore, we examined aggrecan fragments diffusing from normal and OA cartilage explants during a given culture period, using neoepitope Ab that recognize various aggrecan fragments lacking a G1 domain. Age-matched normal and OA cartilage explants were cultured for 72h and supernatants were then analyzed for GAG-content, which is a measure of the loss of degraded aggrecan into the culture media. More GAG was released into the media from OA than normal healthy cartilage over a 72-h culture period (Fig.3b) . We detected no 342 FFGV or 374 ARGS neoepitopes in the supernatants of normal cartilage explants under the experimental conditions employed (Fig. 3b) . Culture media of OA explants contained no detectable MMP-generated 342 FFGV, but in contrast several different sized aggrecan fragments with the N-terminus 374 ARGS were present (Fig. 3b) . Since the AF28 Ab is about 10 times more reactive than the BC3 Ab (unpublished observations), it is unlikely that we are missing MMP-generated fragments.
To confirm that aggrecan fragments difusing from OA cartilage are the result of cleavage by ADAM-TS4/ADAM-TS5, we looked for fragments generated by cleavage at the additional ADAM-TS4 and ADAM-TS5-preferred sites shown in Fig.1 (Fig.3c) , most likely representing the fragment with the 374 ARGS N-terminus.
A larger fragment bearing this epitope was just detectable, probably representing the G1-containing fragment (Fig.3c) . Anti-1715 GLGS detected a 140-kDa fragment, likely representing a fragment containing G3 (Fig.3c) LGQR detected a 98-kDa reactive fragment in the OA cartilage culture medium. The size of the detected fragments is consistent with fragments that are generated when recombinant human ADAM-TS4 and ADAM-TS5 cleave isolated aggrecan monomers (22). Dramatically lower levels of all the aggrecanase-generated fragments were detected in the supernatants from age-matched healthy cartilage (Fig.3c) .
OA cartilage matrix also contained all these ADAM-TS4/ADAM-TS5-generated neoepitopes (Fig.3d) . As anticipated, the larger fragments bearing the KEEE 1667 or the SELE 1545 epitopes were mainly retained in the matrix, and therefore these are most likely the G1-containing fragments. The 374 ARGS-containing fragments were barely detected in the matrix (Fig.3d) , as they have lost the G1 domain that binds hyaluronan. This is also true for fragments with the N-terminus 1820 AGEG and 1920 LGQR. None of the aggrecanase-generated fragments were detected in healthy control cartilage.
In total, we studied OA cartilage from more than 15 donors, aged 50 to 85. In most cases, the cartilage was taken from the femoral head at the time of joint by guest on September 28, 2017
http://www.jbc.org/ Downloaded from replacement. Although all these patients needed hip replacement, the condition of the cartilage was very variable. Two samples were taken from the femoral condyles, one at the time of total knee replacement and one in a patient who underwent amputation of the lower limb because of osteomyelitis. One sample was a patch of fibrillated cartilage on the medial condyle, taken post mortem. We found that detection of aggrecanase-generated aggrecan fragments was a reproducible finding. Fig.4 shows aggrecan fragments eluting out of 10 different OA samples.
Aggrecan degradation in OA cartilage explants is blocked by an "ADAM-TS inhibitor", but not by an " MMP inhibitor".
To confirm that neoepitopes released into the culture medium from OA cartilage was due to aggrecan cleavage occurring during the 72-h culture period and was mediated by ADAM-TS4 and ADAM-TS5, inhibition studies were performed using two different synthetic inhibitors containing a hydroxamic acid group. XS309 is a potent inhibitor of the known MMPs that is ineffective in blocking ADAM-TS4 and ADAM-TS5 at concentrations below 10 µM (referred to as "MMP inhibitor") and
BB-16 is potent in inhibiting both MMPs and ADAM-TS4/ADAM-TS5 (referred to as "ADAM-TS inhibitor") (25).
Explants from normal and OA cartilage were cultured for 72 h in the presence of various concentrations of either XS309 or BB-16. At the end of the culture period, GAG levels in the culture media were determined by DMMB assay (Fig. 5a ). The ADAM-TS inhibitor, BB-16, dose-dependently suppressed the loss of GAG from OA cartilage, with the 10 µM concentration suppressing GAG levels to the base level released by healthy cartilage (Fig.5a) . The MMP inhibitor, XS309, did not block GAG release unless used at 30 µM, a concentration at which this compound also by guest on September 28, 2017
http://www.jbc.org/ Downloaded from inhibits ADAM-TS4 (14, 25) . GAG release into the culture media was found to correlate with the presence of the 374 ARGS neoepitope (Fig.5b) . In a more extensive dose-response experiment, it was found that BB-16 blocked the release of aggrecan fragments bearing the 374 ARGS neoepitope in a dose-dependent manner, with an IC 50 of less than 0.03 µM (Fig.5c) . Inhibition experiments with BB-16 were reproduced in at least 10 independent experiments performed on OA cartilage from different donors.
These findings represent the first demonstration that MMPs are not involved in aggrecan catabolism in OA cartilage.
ADAM-TS4 is induced in OA cartilage whereas ADAM-TS5 is constitutively expressed in both normal and OA cartilage.
RT-PCR was used to analyse freshly obtained human normal and OA cartilage for the presence of ADAM-TS4 and ADAM-TS5 mRNA (Fig.6 ). The former was not found in normal cartilage but was present in OA cartilage, suggesting that ADAM-TS4 is induced in disease. ADAM-TS5 mRNA was present in both normal and OA cartilage, suggesting that this enzyme is constitutively expressed, as described for bovine cartilage (25, 34) . However, more detailed analysis, where samples are matched in terms of age of the donor, gender, and joint location, is required before it can be concluded that this is a typical result.
mRNA results correlated with protein expression as assessed by Western blot analysis. For this purpose, OA cartilage matrix was extracted in 4 M GuCl and fractionated on a CsCl gradient under dissociative conditions. Both ADAM-TS4
( Fig.7a) and ADAM-TS5 (Fig.7b) were found in the low d fractions, but some enzyme could be detected in the 1.6 g/ml d fraction, which is the fraction containing aggrecan.
This may illustrate the tight interaction of the enzyme with its substrate, even under by guest on September 28, 2017 http://www.jbc.org/ Downloaded from stringent denaturing conditions. For ADAM-TS4 the main bands detected were at 98 kDa, 64 kDa, and 30 kDa (Fig.7a) . Based on expression of recombinant human ADAM-TS4 in insect cells, these bands most likely represent the zymogen, the active form of the enzyme in which the propeptide has been removed, and a proteolytic fragment, respectively (14) . For ADAM-TS5, two major bands were detected, a broad band at 70 kDa (ADAM-TS5 has several glycosylation sites, which may explain the broadness of the band), and a C-terminally truncated form at 30 kDa. No band was seen corresponding to the predicted molecular weight of the zymogen. In a different experiment, age-matched normal and OA cartilage were compared. ADAM-TS4 was only detected in OA cartilage, even though the healthy cartilage was taken from a very old donor (89 yr-old) while ADAM-TS5 was found in both OA and healthy cartilage matrix (data not shown).
Aggrecan fragments in OA synovial fluids contain aggrecanase-generated neoepitopes.
Synovial fluids (SF) of OA patients were fractionated on a CsCl gradient and analyzed for the presence of neoepitopes. Most aggrecan fragments were found in the high d fractions D1 and D2. Fig.8 shows the analysis of the SF of a patient with early OA (43 yr-old). No MMP-generated 342 FFGV-containing fragments were detected in any of the fractions D1-D4, whereas the aggrecanase-generated neoepitopes generated neoepitopes were detected in fraction D1 (Fig.9) . The MMP-generated
Discussion
The present findings collectively suggest that aggrecan degradation in OA cartilage is mediated by the cartilage aggrecanases ADAM-TS4 and/or ADAM-TS5, without the participation of MMPs. This is based on (1) cleavage within the C-terminal region of aggrecan are specific for the aggrecanases, as no MMP was able to cleave at these sites, including MMP-8 that does cleave at the classical aggrecanase site between residues Glu 373 -Ala 374 . We are currently exploring the use of neoepitope antibodies as markers for cartilage degradation in OA.
Future studies will focus on which aggrecanase, ADAM-TS4 or ADAM-TS5, is critical for aggrecan catabolism in OA. In addition to monitoring the increase in ADAM-TS4/ADAM-TS5 message and protein, it will be equally important to study the activation of these proteinases as an alternative mechanism for inducing aggrecan catabolism in disease (46). 
